EdgarLookup

Axsome Therapeutics, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Axsome Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q2 2023 Jun 30, 2023 $31.30M Aug 7, 2023
Q3 2022 Sep 30, 2021 $0 Nov 7, 2022
Q2 2022 Jun 30, 2021 $0 Aug 9, 2022

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $170.99M Nov 3, 2025
Q2 2025 Jun 30, 2025 $150.04M Aug 4, 2025
Q1 2025 Mar 31, 2025 $121.46M May 5, 2025
Q3 2025 Sep 30, 2024 $104.76M Nov 3, 2025
Q2 2025 Jun 30, 2024 $87.17M Aug 4, 2025
Q1 2025 Mar 31, 2024 $75.00M May 5, 2025
Q3 2024 Sep 30, 2023 $57.79M Nov 12, 2024
Q2 2024 Jun 30, 2023 $46.70M Aug 5, 2024
Q1 2024 Mar 31, 2023 $94.58M May 6, 2024
Q3 2023 Sep 30, 2022 $16.85M Nov 6, 2023
Q2 2023 Jun 30, 2022 $8.82M Aug 7, 2023

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($47.23M) Nov 3, 2025
Q2 2025 Jun 30, 2025 ($47.97M) Aug 4, 2025
Q3 2025 Jun 30, 2025 ($47.97M) Nov 3, 2025
Q2 2025 Mar 31, 2025 ($59.41M) Aug 4, 2025
Q3 2025 Mar 31, 2025 ($59.41M) Nov 3, 2025
Q1 2025 Mar 31, 2025 ($59.41M) May 5, 2025
Q3 2025 Sep 30, 2024 ($64.60M) Nov 3, 2025
Q3 2025 Jun 30, 2024 ($79.35M) Nov 3, 2025
Q2 2025 Jun 30, 2024 ($79.35M) Aug 4, 2025
Q3 2025 Mar 31, 2024 ($68.36M) Nov 3, 2025
Q1 2025 Mar 31, 2024 ($68.36M) May 5, 2025
Q2 2025 Mar 31, 2024 ($68.36M) Aug 4, 2025
Q3 2024 Sep 30, 2023 ($62.20M) Nov 12, 2024
Q2 2024 Jun 30, 2023 ($67.17M) Aug 5, 2024
Q3 2024 Jun 30, 2023 ($67.17M) Nov 12, 2024
Q1 2024 Mar 31, 2023 ($11.22M) May 6, 2024
Q2 2024 Mar 31, 2023 ($11.22M) Aug 5, 2024
Q3 2024 Mar 31, 2023 ($11.22M) Nov 12, 2024
Q3 2023 Sep 30, 2022 ($44.82M) Nov 6, 2023
Q2 2023 Jun 30, 2022 ($41.44M) Aug 7, 2023

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($46.11M) Nov 3, 2025
Q2 2025 Jun 30, 2025 ($36.71M) Aug 4, 2025
Q1 2025 Mar 31, 2025 ($56.98M) May 5, 2025
Q3 2025 Sep 30, 2024 ($62.62M) Nov 3, 2025
Q2 2025 Jun 30, 2024 ($78.05M) Aug 4, 2025
Q1 2025 Mar 31, 2024 ($67.28M) May 5, 2025
Q3 2024 Sep 30, 2023 ($62.12M) Nov 12, 2024
Q2 2024 Jun 30, 2023 ($65.06M) Aug 5, 2024
Q1 2024 Mar 31, 2023 ($6.37M) May 6, 2024
Q3 2023 Sep 30, 2022 ($42.41M) Nov 6, 2023
Q2 2023 Jun 30, 2022 ($39.18M) Aug 7, 2023
Q1 2023 Mar 31, 2022 ($38.29M) May 9, 2023
Q3 2022 Sep 30, 2021 ($33.41M) Nov 7, 2022
Q2 2022 Jun 30, 2021 ($30.85M) Aug 9, 2022
Q1 2022 Mar 31, 2021 ($27.84M) May 2, 2022
Q3 2021 Sep 30, 2020 ($21.13M) Nov 8, 2021
Q2 2021 Jun 30, 2020 ($17.78M) Aug 9, 2021
Q1 2021 Mar 31, 2020 ($32.49M) May 10, 2021
Q3 2020 Sep 30, 2019 ($18.95M) Nov 5, 2020
Q2 2020 Jun 30, 2019 ($13.45M) Aug 10, 2020